Canary Capital has filed with the U.S. Securities and Change Fee to launch the first-ever staked Injective (INJ) exchange-traded fund, aiming to offer institutional buyers with regulated entry to native on-chain yield.
The proposed Canary Staked INJ ETF would actively stake its INJ holdings on the Injective proof-of-stake community, passing staking rewards, at present estimated at 10% to 12% yearly, on to shareholders.
It additionally alerts rising market confidence in Injective’s ecosystem, which has attracted strategic backing from companies like Google Cloud and T-Cell.
Injective Labs can also be actively engaged in ongoing discussions with U.S. regulators to outline compliant pathways for decentralized finance.
Broader ETF technique
The INJ ETF is a component of a bigger push by Canary Capital, a agency led by former Valkyrie CIO Steven McClurg, to convey high-yield digital property into conventional market constructions.
Canary has already filed for ETFs tied to Solana, XRP, Hedera, Sui, and the Pudgy Penguins NFT mission. A number of of those functions embrace staking parts, equivalent to its Marinade-powered Solana ETF, positioning the agency as a frontrunner in staking-integrated funding merchandise.
Canary established a Delaware statutory belief to help the INJ fund, mirroring its earlier filings and signaling intent to fulfill the SEC’s evolving expectations round custodianship, validator choice, and yield therapy.
The proposal lands throughout Crypto Week 2025, as lawmakers debate a number of payments that might outline the authorized framework for staking and different crypto-native actions. With SEC management now extra open to structured yield merchandise, Canary’s timing displays a calculated guess on a regulatory shift.
A number of issuers need to embrace staking in upcoming ETFs. Some have additionally filed to activate staking for spot Ethereum ETFs which can be already dwell, together with BlackRock.